SE0102858D0 - N-type calcium channel antagonists for the treatment of pain - Google Patents

N-type calcium channel antagonists for the treatment of pain

Info

Publication number
SE0102858D0
SE0102858D0 SE0102858A SE0102858A SE0102858D0 SE 0102858 D0 SE0102858 D0 SE 0102858D0 SE 0102858 A SE0102858 A SE 0102858A SE 0102858 A SE0102858 A SE 0102858A SE 0102858 D0 SE0102858 D0 SE 0102858D0
Authority
SE
Sweden
Prior art keywords
sup
treatment
pain
calcium channel
type calcium
Prior art date
Application number
SE0102858A
Other languages
English (en)
Swedish (sv)
Inventor
Amico Derin D
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0102858A priority Critical patent/SE0102858D0/xx
Publication of SE0102858D0 publication Critical patent/SE0102858D0/xx
Priority to US10/488,025 priority patent/US7153865B2/en
Priority to EP02760975A priority patent/EP1430030B1/de
Priority to JP2003523224A priority patent/JP2005508894A/ja
Priority to AT02760975T priority patent/ATE295837T1/de
Priority to DE60204232T priority patent/DE60204232T2/de
Priority to PCT/SE2002/001521 priority patent/WO2003018561A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0102858A 2001-08-27 2001-08-27 N-type calcium channel antagonists for the treatment of pain SE0102858D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE0102858A SE0102858D0 (sv) 2001-08-27 2001-08-27 N-type calcium channel antagonists for the treatment of pain
US10/488,025 US7153865B2 (en) 2001-08-27 2002-08-23 N-type calcium channel antagonists for the treatment of pain
EP02760975A EP1430030B1 (de) 2001-08-27 2002-08-23 Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen
JP2003523224A JP2005508894A (ja) 2001-08-27 2002-08-23 痛みの治療のためのn型カルシウムチャネルアンタゴニスト
AT02760975T ATE295837T1 (de) 2001-08-27 2002-08-23 Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen
DE60204232T DE60204232T2 (de) 2001-08-27 2002-08-23 Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen
PCT/SE2002/001521 WO2003018561A1 (en) 2001-08-27 2002-08-23 N-type calcium channel antagonists for the treatment of pain

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102858A SE0102858D0 (sv) 2001-08-27 2001-08-27 N-type calcium channel antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
SE0102858D0 true SE0102858D0 (sv) 2001-08-27

Family

ID=20285150

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0102858A SE0102858D0 (sv) 2001-08-27 2001-08-27 N-type calcium channel antagonists for the treatment of pain

Country Status (7)

Country Link
US (1) US7153865B2 (de)
EP (1) EP1430030B1 (de)
JP (1) JP2005508894A (de)
AT (1) ATE295837T1 (de)
DE (1) DE60204232T2 (de)
SE (1) SE0102858D0 (de)
WO (1) WO2003018561A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004080444A2 (en) * 2003-03-10 2004-09-23 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators
US7223754B2 (en) 2003-03-10 2007-05-29 Dynogen Pharmaceuticals, Inc. Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
CA2518398A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
WO2005000285A2 (en) * 2003-06-13 2005-01-06 Dynogen Pharmaceuticals, Inc. METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS
US20060128702A1 (en) * 2004-11-23 2006-06-15 Manojit Pal Heterocyclic and bicyclic compounds, compositions and methods
EP1963280B1 (de) 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylaminoderivate als calcium- und/oder natrium-kanalmodulatoren
DK2155663T3 (en) 2007-06-15 2018-01-22 Newron Pharm Spa SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND / OR CALCIUM CHANNEL MODULATORS
WO2011054433A1 (en) 2009-11-07 2011-05-12 Merck Patent Gmbh Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
EA022973B1 (ru) 2011-06-27 2016-03-31 Ньюрон Фармасьютикалс С.П.А. Фторированные арилалкиламинокарбоксамидные производные
CA3217159A1 (en) * 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Substituted quinazolin-4-amine compounds and pharmaceutical compositions thereof having anti-inflammatory, antifungal, antiparasitic and anticancer activity
WO2014159837A1 (en) 2013-03-14 2014-10-02 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
WO2017091661A1 (en) 2015-11-25 2017-06-01 Strovel Jeffrey William Bicyclic bet bromodomain inhibitors and uses thereof
JP6965432B2 (ja) * 2017-08-29 2021-11-10 チュラポーン ファンデーション キノリンおよびナフチリジンの誘導体および組成物
EP3958867B1 (de) 2019-04-24 2024-06-26 Convergene Llc Kleinmolekulare bromodomänenhemmer und verwendungen davon
AU2022380831A1 (en) * 2021-11-05 2024-06-06 Chinese University Of Hong Kong, Shenzhen Alpha-2a adrenergic receptor modulators and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1573186A (en) * 1977-09-14 1980-08-20 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
AU4802500A (en) * 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands

Also Published As

Publication number Publication date
EP1430030A1 (de) 2004-06-23
EP1430030B1 (de) 2005-05-18
ATE295837T1 (de) 2005-06-15
WO2003018561A1 (en) 2003-03-06
US20050131020A1 (en) 2005-06-16
US7153865B2 (en) 2006-12-26
DE60204232T2 (de) 2006-01-26
DE60204232D1 (de) 2005-06-23
JP2005508894A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
SE0004053D0 (sv) N-type calcium channel antagonists for the treatment of pain
EA200401169A1 (ru) Аминометилзамещенные тетрациклиновые соединения
NO20026064D0 (no) Nye forbindelser
SE0102315D0 (sv) Compounds
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
ATE365703T1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate,deren herstellung und anwendungen
DE60204232D1 (de) Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen
CY1108808T1 (el) Ενωσεις μοτιλιδης
SE0302139D0 (sv) Novel compounds
SE0004054D0 (sv) N-type calcium channel antagonists for the treatment of pain
SE9802208D0 (sv) Novel compounds
SE0003476D0 (sv) Compounds
SE0203070D0 (en) Novel compounds
DE50310579D1 (de) Furancarboxamide
SE0303280D0 (sv) Novel compounds
SE0203300D0 (sv) Novel Compounds
SE9802209D0 (sv) Novel compounds
SE0302755D0 (sv) Novel compounds
SE9504662D0 (sv) New compounds
DE50311756D1 (de) Mikrobizide oxathiincarboxamide
SE0004056D0 (sv) N-type calcium channel antagonists for the treatment of pain
SE0004055D0 (sv) N-type calcium channel antagonists for the treatment of pain
SE0102857D0 (sv) N-type calcium channel antagonists for the treatment of pain
DE60325079D1 (de) Naphthamidderivate und deren verwendung
SE0203301D0 (sv) Novel Compounds